
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Your AI-Trained Oncology Knowledge Connection!


Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Ann LaCasce, MD, MMSc, discusses the effects that chemotherapy drug shortages may have on clinical trials and patient accrual.

Ann S. LaCasce, MD, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

Published: December 9th 2014 | Updated: